SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
HuMAB companies
An SI Board Since May 2000
Posts SubjectMarks Bans
1022 55 0
Emcee:  nigel bates Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
447Rick instead of cat they should beter buy DYAX royalties on d2e7 are 3% for catdalroi-11/1/2002
446chuckle. (eom)scaram(o)uche-10/29/2002
445CAT?! Wow. I never thought I would see you type in a three letter symbol! <Harold Engstrom-10/29/2002
444I feel that both companies should save their money to invest in CAT. :-) Rick scaram(o)uche-10/29/2002
443Really? I thought design contract had just been awarded a few months ago...Harold Engstrom-10/29/2002
442Harold >> I think use of funds to build an ($100MM-$200MM?) expansion witIcebrg-10/29/2002
441To date, we have seen a shortage of capacity for cell culture processes. But, aHarold Engstrom-10/29/2002
440Harold No, they plan to finish the plant expansion and use the manufacturing caIcebrg-10/29/2002
439Does this mean their current plans to expand their manufacturing capacity are onHarold Engstrom-10/29/2002
438Abgenix are saying today (in the CC) that they are scaling down their operationsIcebrg-10/29/2002
437The price of the Morphoysis license with Xoma is more than $3 million. The $3 maknahow-10/27/2002
436Or how about Genmab? Get the best of both mAb technologies in-house. AdmittedJFitnich-10/24/2002
435The price of the XOMA licence - about $3m in today's Morphosys stock (7.7% onigel bates-10/24/2002
434Morphosys will be sucking on air soon - Message 18145907 Presents interesting nigel bates-10/23/2002
433BERKELEY, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 16, 2002--XOMA Ltnigel bates-10/16/2002
432quote.bloomberg.com News on Iressa in Japanewolf-10/15/2002
431IGEN Launches M-SERIES(R) Application to Facilitate Development Of Monoclonal Annigel bates-10/15/2002
430Comments of potential interest from the CRXL results statement - <i>The mnigel bates-10/14/2002
429Thanks, Miljenko (and Rick) for dissipating some of the fog which envelops my unnigel bates-10/4/2002
428<I don't have an answer to the question - not that it doesn't worry mMiljenko Zuanic-10/3/2002
427<i>...D2E7 would experience the highest growth rate of the class, expandinnigel bates-10/3/2002
426Monoclonal antibody drug sales soaring -report Tuesday October 1, 6:59 pm ET keokalani'nui-10/3/2002
425one more comment before we leave this discussion behind (....... :-)....... iscaram(o)uche-10/2/2002
424With ABGX/CRGN vs CAT/HGSI, the resources (and targets) available to each partnenigel bates-10/2/2002
423>> Interesting snippet from today's CRGN PR << 1. If you injecscaram(o)uche-10/2/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News